Document:

Exhibit 10.1

 

FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT

 

This First Amendment to Securities Purchase Agreement
(the “Agreement”) is entered into this 14th day of March, 2022, by and among Edoc Acquisition Corp., a company organized
under the laws of the Cayman Islands with headquarters located at 7612 Main Street Fishers, Suite 200, Victor, New York (the “Company”),
and the investors listed on the Schedule of Buyers attached hereto (the “Buyer” and collectively with the Company “Parties”
and each a “Party”).

 

WHEREAS, the Company, and Buyer entered into that
certain Securities Purchase Agreement dated February 2, 2022, for the purchase of 20,000 shares of the Company’s Series A Preferred
Stock and 500,000 shares of the Company’s Common Stock by the Buyer together with a warrant to purchase shares of the Company’s
Common Stock (the “Warrant”) for an aggregate purchase of Twenty Five Million Dollars ($25,000,000) (the “SPA”);
and

 

WHEREAS, the Parties now desire to amend the SPA
as set forth herein below.

 

NOW THEREFORE, in exchange for the mutual covenants
set forth below, and other valuable consideration, the Parties agree as follows:

 

1. Clarification
to Section 4(aa)(xii) of the SPA. Sections 4(aa)(xii) and 5(e) of the SPA, Section 4(c)(ii) of the Certificate of Designation, and
Section 1(c) of the Warrant is hereby amended (x) to clarify that so long as the Company has provided notice to the Buyer that the then
effective Registration Statement covering the applicable resale of the Conversion Shares, Common Shares and/or Warrant Shares is not available
in accordance with the requirements of the Registration Rights Agreement (at a time when such Registration Statement is not available
for such applicable securities), then damages with respect to any such “Notice Failure” (as used in such sections) with respect
thereto shall cease to accrue with respect to such Registration Statement as of the time of such notice; provided that, thereafter, if
a registration statement becomes available and later unavailable, the Company shall be required to provide an additional notice for damages
with respect to such “Notice Failure” to cease to accrue with respect thereto and (y) such that the reference to 2% in Section
4(c)(ii) in the form of Certificate of Designation shall be replaced with 1%.

 

2. Additional
Buyers in SPA.  So long as the Buyer has the unconditional right to terminate the SPA, the Company may introduce to the Buyer possible
investors who may be interested in co-investing with the Buyer as additional Buyers on terms no less favorable than the terms set forth
in the SPA. Any such co-investor would be added to the SPA only by an amendment mutually acceptable to the Buyer, the Company, and the
Target Company.

 

23. Other
Provisions of SPA Remain in Full Force and Effect. All other provisions of the SPA remain in full force and effect as written.

 

     

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

	 	COMPANY:
	 	 	 	 
	 	EDOC ACQUISITION CORP.
	 	 	 	 
	 	By: 	
	 	 	Name: 	Kevin Chen
	 	 	Title:	Chief Executive Officer

 

	TARGET COMPANY:	 
	 	 	 	 
	Acknowledged and agreed by:	 
	 	 	 	 
	CALIDI BIOTHERAPEUTICS, INC.,	 
	 a Delaware corporation	 
	 	 	 	 
	By:  		 
	 	Name: 	Allan J. Camaisa	 
	 	Title:	Chief Executive Officer	 

 

Signature Page to the First Amendment to Securities
Purchase Agreement

 

     

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

	 	
    BUYER:

	 	
     

	 	 
	 	 

 

Signature Page to the
First Amendment to Securities Purchase AgreementEX-4.3

   

  Exhibit 4.3

  DESCRIPTION OF THE REGISTRANT’S SECURITIES 

  REGISTERED PURSUANT TO SECTION 12 OF 

  THE SECURITIES EXCHANGE ACT OF 1934

  The following is a description of the common stock, $0.001 par value per share (“common stock”) of Cytek Biosciences, Inc. (the “Company,” “we,” “our,” or “us”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary description is based on the provisions of our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), our Amended and Restated Bylaws (the “Bylaws”), and the applicable provisions of the Delaware General Corporation Law (the “DGCL”). This information may not be complete in all respects and is qualified entirely by reference to the provisions of our Certificate of Incorporation and our Bylaws, which are filed as exhibits to our Annual Report on Form 10-K of which this exhibit is a part.

  General

  Our Certificate of Incorporation authorizes us to issue up to 1,000,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. 

  Common Stock

  Voting Rights

  Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our Certificate of Incorporation, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election.

  Dividend Rights

  Subject to preferences that may apply to any then-outstanding preferred stock, the holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. We do not anticipate paying any cash dividends in the foreseeable future.

  Liquidation Rights

  In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.

  Preemptive or Similar Rights

  Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.

  Preferred Stock

  Under our Certificate of Incorporation, our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of any or all of the 10,000,000 shares of preferred stock authorized in one or more series and authorize their issuance. These rights, preferences, privileges and restrictions could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Any issuance of preferred stock could adversely affect the voting power of holders of 

   

  

   

  common stock and the likelihood that such holders would receive dividend payments and payments on liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. As of December 31, 2021, we have no shares of preferred stock issued and outstanding. We have no present plans to issue any shares of preferred stock. For a complete description of the terms and provisions of the Company’s preferred stock refer to our Certificate of Incorporation and our Bylaws.

  Anti-Takeover Provisions

  Section 203 of the Delaware General Corporation Law

  We are subject to Section 203 of DGCL, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

    

  				
	  
	•
	  
	before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

    

  				
	  
	•
	  
	upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation;

    

  				
	  
	•
	  
	outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

    

  				
	  
	•
	  
	on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder.

  In general, Section 203 defines a “business combination” to include the following:

    

  				
	  
	•
	  
	any merger or consolidation involving the corporation and the interested stockholder;

    

  				
	  
	•
	  
	any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

    

  				
	  
	•
	  
	subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

    

  				
	  
	•
	  
	any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

    

  				
	  
	•
	  
	the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.

  In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

  A Delaware corporation may “opt out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders’ amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.

  Certificate of Incorporation and Bylaws 

  Among other things, our Certificate of Incorporation and our Bylaws:

    

   

  

   

  				
	  
	•
	  
	permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control;

    

  				
	  
	•
	  
	provide that the authorized number of directors may be changed only by resolution of our board of directors;

    

  				
	  
	•
	  
	provide that our board of directors is classified into three classes of directors;

    

  				
	  
	•
	  
	provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;

    

  				
	  
	•
	  
	provide that all vacancies, including newly created directorships, may, unless the board of directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

    

  				
	  
	•
	  
	require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;

    

  				
	  
	•
	  
	provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice;

    

  				
	  
	•
	  
	provide that special meetings of our stockholders may be called only by the chairperson of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and

    

  				
	  
	•
	  
	not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.

  The amendment of any of these provisions requires approval by the holders of at least 66 2/3% of the voting power of all of our then-outstanding capital stock entitled to vote generally in the election of directors, voting together as a single class.

  The combination of these provisions makes it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

  These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock.

  Choice of Forum

  Our Certificate of Incorporation and our Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former 

   

  

   

  directors, officers, or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws; (iv) any action or proceeding to interpret, apply, enforce, or determine the validity of our Certificate of Incorporation or our Bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers, or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act of 1933, as amended (the “Securities Act”) creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Certificate of Incorporation and our Bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our Certificate of Incorporation and our Bylaws.

  These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find either exclusive forum provision contained in our Certificate of Incorporation or our Bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could seriously harm our business. 

  Corporate Opportunity Doctrine

  The DGCL permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. Our Certificate of Incorporation, to the extent permitted by the DGCL, renounces any expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to a member of our board of directors who is not our employee, or any partner, member, director, stockholder, employee or agent of such member, other than who is an employee of the Company. Notwithstanding the foregoing, our Certificate of Incorporation does not renounce our interest in any business opportunity that is expressly offered to a director solely in their capacity as a director.

  Exchange Listing

  Our common stock is listed on the Nasdaq Global Select Market under the symbol “CTKB.”

  Transfer Agent and Registrar

  The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent’s address is 6201 15th Avenue, Brooklyn, NY 11219 and the telephone number is (800) 937-5449.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]